What it sells
Specialty drug adherence tech.
Business model breakdown
Buyer: who owns the budget?
UnverifiedCommercial, patient services and field reimbursement leaders at biopharma companies.
Trigger: what makes them buy now?
Getting patients to start and stay on specialty therapy: manual intake work blocks starts; e.g. Madrigal pairs its newly approved MASH therapy with Courier Health technology.
Workflow: what inputs become what output?
Unify patient data across the access ecosystem into one journey view; orchestrate the next action for each patient; AI intake automates manual enrollment work; engagement tools measure outcomes.
Economics: what it saves and how it charges
Claimed customer results: over 40% improvement in time to therapy, over 15% increase in patient starts, over 10% uplift in 6-month persistency. Raised a $50M Series B.
Distribution: how it reaches customers
Enterprise sales ("Contact us"); thought leadership such as the State of Patient-Centricity in Biopharma 2026 report.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-04-23 | — | $50M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.